In the MOLM-13Luc AML-bearing mice, we observed that there was no difference in the number of residual CD4+ and CD8+ T cells in the BM and PB of mice (Supplementary Figs. 10a, b and 11a, b) or the number of residual CD4+ and CD8+ CAR T cells that were PD-1negative TIM-3negative between the treatment groups (Supplementary Figs. 10c, d and 11c, d). The gene discussed is CD8A; the disease is acute myeloid leukemia.